CDK 4/6 Inhibition in Metastatic ER+ Breast Cancer

Kimberly L. Blackwell ASCO 2017 Research To Practice


Disclosures

Advisory Committee	Eisai Inc, MacroGenics Inc, Merck, Novartis, Pfizer Inc, Pierian Biosciences, Syndax Pharmaceuticals Inc
Consulting Agreements	Celgene Corporation, Coherus BioSciences, G1 Therapeutics, Genentech BioOncology, Lilly, Puma Biotechnology, Sandoz, Novartis, Pfizer, Roche Laboratories Inc
Contracted Research	Celgene Corporation, Genentech BioOncology, Novartis, Pfizer Inc

CDK 4/6 Inhibitors in Clinical Development


Drug name	Status	Year
Palbociclib	FDA approved. 1 st line therapy ER+, HER2- metastatic breast cancer, 2 nd line	2015
Ribociclib (LEE011)	FDA approved, Phase III clinical trials.	2017
Abemaciclib (LY2853219)	Phase III clinical trials. FDA breakthrough designation.	?

PALOMA-1 Study Design ER+, HER2– Locally Recurrent or Metastatic Breast Cancer




No prior/current brain metastases

PALOMA-1 Study Design ER+, HER2– Locally Recurrent or Metastatic Breast Cancer




The Lancet Oncology 2015 16, 25-35DOI: (10.1016/S1470-2045(14)71159-3)

PALOMA-1 OS: Phase 2 (ITT)




Finn, ASCO, 2017

PALOMA-2: Phase 3 Study Palbociclib Plus Letrozole as First-Line Therapy in HR+, HER2–ABC



ABC, advanced breast cancer; ER+, estrogen receptor-positive; ET, endocrine therapy; HER2–, human epidermal growth factor receptor-2–negative; HR+, hormone receptor-positive; mo, months. Finn RS, et al. *N Engl J Med*. 2016;375(20):1925-1936.

PALOMA-3: Phase 3 Study of CDKi (Palbociclib) Plus Fulvestrant in HR+, HER2–ABC



ABC, advanced breast cancer; AE, adverse event; CDKi, cyclin-dependent kinase inhibitor;


CI, confidence interval; ET, endocrine therapy; FUL, fulvestrant; HT, hormonal therapy;

LET, letrozole; HER2–, human epidermal growth factor receptor-2–negative; HR, hazard ratio; HR+, hormone receptor-positive; PAL, palbociclib; PBO, placebo; PFS, progression-free survival.

1. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439; 2. Turner NC, et al. SABCS 2016. Abstract P4-22-06 [poster].


Ribociclib + Letrozole Demonstrate Anti-Tumor Activity

Inhibition of tumor growth in ER+ breast cancer xenograft model HBX34¹



- ER+, estrogen receptor-positive; HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive;
 - PD, progressive disease; QD, once daily.
 - 1. O'Brien NA, et al. AACR 2014, abstr 4756 (oral); 2. Juric D, et al. ASCO 2016, abstr 568 (poster).

MONALEESA-2: A Phase 3, Double-Blind, Placebo-Controlled Study of Ribociclib + Letrozole




- Tumor assessments were performed every 8 weeks for 18 months, then every 12 weeks thereafter
- Final analysis planned after 302 PFS events
 - 93.5% power to detect a 33% risk reduction (HR 0.67) with one-sided $\alpha\text{=}2.5\%$

^a Ribociclib 600 mg per day, 3-weeks-on/1-week-off; letrozole 2.5 mg/day.

^bWith supportive independent central review; MONALEESA-2 is registered at ClinicalTrials.gov (NCT01958021).

CBR, clinical benefit rate; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors. Hortobagyi G, et al. N Engl J Med. 2016;375(18):1738-1748.

MONALEESA-2 Met the Primary Endpoint at Interim/ASCO 2017




PFS results by independent central review: hazard ratio 0.592 (95% CI: 0.412–0.852; p=0.002) PFS results (ASCO 2017): HR of 0.568; p=0.000000009 25.3 vs. 16.0 months OS (ASCO 2017): HR of 0.746; p= 0.059 NR vs. 33.0 months

Hematologic Adverse Events

Adverse Event	Ribo	ciclib + Letro n=334	ozole	Placebo + Letrozole n=330			
≥5% In Either Arm, %	All	Grade 3	Grade 4	All	Grade 3	Grade 4	
Neutropenia	74.3	49.7	9.6	5.2	0.9	0	
Leukopenia	32.9	19.8	1.2	3.9	0.6	0	
Anemia	18.6	0.9	0.3	4.5	1.2	0	
Lymphopenia	10.5	5.7	1.2	2.1	0.9	0	
Thrombocytopenia	9.0	0.6	0	0.6	0	0	

Febrile neutropenia occurred in 1.5% of patients in the ribociclib arm vs. none in the placebo arm


MONALEESA-7: Ribociclib + Letrozole + Goserelin for Premenopausal Women With HR+, HER2– ABC



ABC, advanced breast cancer; CBR, clinical benefit rate; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; ET, endocrine therapy; HER2–, human epidermal growth factor receptor-2–negative; HR+, hormone receptor-positive; NSAI, nonsteroidal aromatase inhibitor; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PS, performance status; QoL, quality of life; RECIST, Response Evaluation Criteria in Solid Tumors; TTR, time to response.

^a Ribociclib or placebo (600 mg) given once daily for 21 days followed by a 7-day break (28-day cycle); letrozole (2.5 mg), anastrozole (1 mg), tamoxifen (20 mg) given on a continuous dosing schedule (28-day cycles); goserelin (3.6 mg) given on day 1 of each 28-day cycle. www.clinicaltrials.gov (NCT02278120).

MONALEESA-3: Ribociclib + Fulvestrant for PreMenopausal and Postmenopausal Women With HR+, HER2– ABC




- Enrollment complete May 2016
- Stratification will be based on the presence of lung or liver metastases and prior ET

^aRibociclib or placebo (600 mg) given once daily for 21 days followed by a 7-day break (28-day cycle); fulvestrant (500 mg) given IM on Days 1 and 15 of Cycle 1 and Day 1 of each cycle thereafter

ABC, advanced breast cancer; CBR, clinical benefit rate; ctDNA, circulating tumor DNA; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; HRU, hospital resource utilization; IM, intramuscular; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetics; PRO, patient-reported outcomes; QD, once daily; RIB, ribociclib; TTR, time to response.

Fasching PA, et al. SABCS 2015; Abstract OT2-01-02 (poster); www.clinicaltrials.gov (NCT02422615).

MONARCH 1: Phase 2 Study Design



Drimorri abiadiria

- Median number of prior systemic regimens (any setting) was 5 (range 2-11)
- 100% of patients received taxanes in any setting
- Median number of prior systemic regimens for metastatic disease was 3 (range 1-8)


Endocrine Therapy for Metastatic Disease	N=132 n (%)	Chemotherapy for Metastatic Disease	N=132 n (%)	
# of Regimens		# of Regimens		
1	48 (36.4)	1	67 (50.8)	
2	25 (18.9)	2	64 (48.5)	
3	24 (18.2)	3	1 (0.8)	
≥ 4	18 (13.6)	Taxanes	91 (68.9)	
Prior fulvestrant	67 (50.8)	Capecitabine	73 (55.3)	

Dickler, SABCS, 2016


MONARCH 1: Response Summary

	Investigator Assessed Response ^a	Abemaciclib 200 mg (N = 132)
100-	Confirmed Objective Response Rate (ORR = CR + PR) (95% Cl)	19.7% (13.3, 27.5)
(%	CR PR	0% 19.7%
© 50− ອ	Stable Disease ≥6 months	22.7%
selir 20-	Clinical Benefit Rate (CBR = ORR +SD ≥6 mos)	42.4%
bas		
ge from baseline (%) - 05 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0		
Change -30 -00- Change	Disease Control Rate (CR + PR + SD) = 67.4%	
-100-	Progressive disease (n = 34) Stable disease (n = 63) Partial response (n = 26) Not assessed (n = 9) ^a Assessments based on independent review were	comparable

MONARCH 1: Treatment Duration



MONARCH-2 Study Design




- Statistics: 378 events for 90% power at one-sided α of .025 assuming a true HR of .703

^aRequired to receive GnRH agonist ^bDose reduced by protocol amendment in all new and ongoing patients from 200 mg to 150 mg BID after 178 patients enrolled ^cFulvestrant administered per label

Sledge, ASCO, 2017

MONARCH 2: Primary Endpoint: PFS (ITT)



TEAE (Safety Population)

abemaciclih + fulvestrant

	abe				placebo + luivestialit		
	n = 441				n = 223		
\geq 20% in either arm, n (%)	All	G3	G4	All	G3	G4	
Any	435 (98.6)	241 (54.6)	26 (5.9)	199 (89.2)	46 (20.6)	5 (2.2)	
Diarrhea ^a	381 (86.4)	59 (13.4)	0	55 (24.7)	1 (0.4)	0	
Neutropenia ^b	203 (46.0)	104 (23.6)	13 (2.9)	9 (4.0)	3 (1.3)	1 (0.4)	
Nausea	199 (45.1)	12 (2.7)	-	51 (22.9)	2 (0.9)	-	
Fatigue	176 (39.9)	12 (2.7)	-	60 (26.9)	1 (0.4)	-	
Abdominal pain	156 (35.4)	11 (2.5)	-	35 (15.7)	2 (0.9)	-	
Anemia	128 (29.0)	31 (7.0)	1 (0.2)	8 (3.6)	2 (0.9)	0	
Leukopenia	125 (28.3)	38 (8.6)	1 (0.2)	4 (1.8)	0	0	
Decreased appetite	117 (26.5)	5 (1.1)	0	27 (12.1)	1 (0.4)	0	
Vomiting	114 (25.9)	4 (0.9)	0	23 (10.3)	4 (1.8)	0	
Headache	89 (20.2)	3 (0.7)	-	34 (15.2)	1 (0.4)	-	

^aGrade 2 diarrhea: abemaciclib + fulvestrant n=140 (31.7%); placebo + fulvestrant n=11 (4.9%). ^bFebrile neutropenia was uncommon [6 patients in the abemaciclib arm (1 incorrectly coded; 1 postchemotherapy)] and was not associated with severe infection